The snack and beverage giant PepsiCo ($PEP) is set to release its third quarter 2024 financials on October 8. Wall Street ...

INDY ETF is currently exceeding the average returns it generates in a calendar year. Read why we wouldn’t be comfortable ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.